Legacy Advisors LLC Acquires 7,598 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Legacy Advisors LLC increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 54.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,534 shares of the biopharmaceutical company's stock after acquiring an additional 7,598 shares during the quarter. Legacy Advisors LLC's holdings in Bristol Myers Squibb were worth $1,313,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in BMY. Pinney & Scofield Inc. bought a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $26,000. Global Wealth Strategies & Associates lifted its stake in Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares during the period. Transce3nd LLC bought a new position in shares of Bristol Myers Squibb in the fourth quarter valued at $28,000. Finally, Fairway Wealth LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at $28,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

BMY traded down $0.31 during trading on Friday, hitting $46.34. The stock had a trading volume of 21,851,928 shares, compared to its average volume of 12,915,665. Bristol Myers Squibb Company has a twelve month low of $39.35 and a twelve month high of $63.33. The firm has a market capitalization of $94.31 billion, a P/E ratio of 17.36, a PEG ratio of 1.38 and a beta of 0.38. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The company's 50-day moving average price is $47.96 and its 200 day moving average price is $54.02.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm's revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the company earned ($4.40) EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be issued a $0.62 dividend. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.35%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on BMY. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Piper Sandler initiated coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. UBS Group decreased their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Jefferies Financial Group reduced their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Finally, Wall Street Zen cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $58.00.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.09% of the stock is owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.